Health Care • Biotechnology: Pharmaceutical Preparations
$3.26 ▲ +0.14
(+4.49%)
MKT CAP: $92.9M • VOL: 131.7K
52W L $3 52W H $12
ROARABLE / RQD
E • 33/100
PIOTROSKI
1 / 9
NTHI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $40.0K | $83.0K |
| YoY Revenue Growth % | -51.8% | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$58.2M | -$7.1M |
| Operating Margin % | -80.0% | -80.0% |
| Net Income (GAAP) | -$62.1M | -$11.9M |
| EBITDA (Normalized) | — | — |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$20.4M | -$4.2M |
| Capital Expenditures (CapEx) | — | — |
| Free Cash Flow (FCF) | -$20.4M | -$4.2M |
| FCF Margin % | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $58.7K | $64.9K |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | -$17.5M | -$5.5M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NTHI.